Is DR Just the Start for Google Brain?

A team of investigators recently reported online in the Journal of the American Medical Association1 that a Google algorithm allows computers to diagnose diabetic retinopathy (DR) using retina photos. The technology will never replace doctors, but Google hopes it will assist them, especially in underserved areas. Google’s first priority with this technology is to distribute…

Read More

Eye on Five – January Edition

OIS-Eye-On-Five

Alcon Turnaround Has Novartis Exploring Spin-off With its Alcon turnaround plans on track, Novartis AG revealed it is exploring options that include spinning off Alcon or issuing an IPO for the eye-care unit – or even keeping it. Alcon lost $120 million in fourth-quarter 2016 and $132 million for the year versus a profit of…

Read More

Is Trump Opening New Front in War on Drug Prices?

Pharma executives were beaming as their stock prices soared in the days after Donald Trump’s poll-defying victory, and their sentiments rose even higher with the defeat of a California ballot initiative that would have instituted price controls on state-purchased drugs. Then Trump held his first post-election press conference last week, saying that pharma was “getting…

Read More

What Now? What Does Ophthotech’s Disappointing Phase III Results Mean for Wet AMD, VEGF and PDGF?

OIS Podcast - What Now? What Does Ophthotech’s Disappointing Phase III Results Mean for Wet AMD, VEGF and PDGF? - Healthegy - Eye On Innovation

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 115″] KOLs, CEOs, and analysts say Ophthotech’s disappointing Fovista trials alter the landscape for companies developing new treatments for wet AMD. And all agree, the biggest losers in all of this are patients suffering from the disease. Transcript Tom Salemi: Hey, everybody, welcome back to the OIS Podcast. This is the…

Read More

After Stunning Phase III Results, Ophthotech Seeks a Path Forward

Eye On Innovation Article - After stunning Phase 3 results, Ophthotech seeks a path forward - Healthegy

After disappointing Phase III results of Fovista (pegpleranib) in combination with Lucentis (ranibizumab, Genentech) sent its stock reeling, Ophthotech Corporation is reevaluating not only the trial data but also how the results will impact ongoing Fovista combination trials as well as its overall business. And while Ophthotech may have the equivalent of financial pneumonia, if…

Read More

Welcome to OIS@AAO 2016

Welcome to OIS@AAO 2016 - Eye On Innovation Article - OIS - Healthegy

More than 800 leaders of the ophthalmology industry will convene Thursday at the Hyatt Regency Chicago Hotel ballroom for our largest Ophthalmology Innovation Summit of the year. This is the 8th OIS@AAO held prior to the annual meeting of the American Academy of Ophthalmology. Registration and check-in for those attending the Breakfast Breakout Sessions will…

Read More

LacriScience Enters Next Chapter

Chris D. Geddes, Ph.D, and Paul Gavaris of LacriScience share the prototype of the LacriPen, a handheld, portable, diagnostic tool that measures osmolarity to within 2 mOsml and can detect other viruses and bacteria including Methicillin-resistant Staphylococcus aureus (MRSA). Highlights 00:24 – “This has been a pivotal moment.” 00:53 – “We’ve had a lot of traction…

Read More

Emptying the OIS Reporter’s Notebook After OIS@AAO

OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 069″] OIS Correspondents Michelle Dalton and Richard Kirkner pool their insights on the most compelling sights and insights of OIS, Subspecialty Day and AAO. The two scribes opine on exiting new disease targets, advances in drug delivery, the penetration of digital technology and why the `Pfizergan’ deal makes sense for ophthalmology.…

Read More

Gobiquity

With only one in five children who have risk factors for amblyopia getting tested, Gobiquity Mobile Health is continuing to develop its smartphone-based early screening technology to break down those barriers, CEO Andrew Burns said at OIS@AAO 2015. Gobiquity’s GoCheck Kids app is the first to perform photo-screening and provide real-time analysis to show if…

Read More

Amblyotech

Amblyotech CEO Joseph Koziak describes the company as a “hybrid” life science and software company that is refining its tablet-based treatment platform for amblyopia in adolescents and adults. Its Dig Rush is the first therapeutic video game that treats amblyopia, Koziak said at OIS@AAO 2015. It’s an alternative to patching, which can cost up to…

Read More

DigiSight Technologies

DigiSight Technologies announced at OIS@AAO 2015 that it was launching its Paxos product suite that combines its mobile vision assessment tool, ophthalmic imaging system and analytics software into a vertically integrated data management system. “When you put these devices into patients’ homes, for the first time you can access the vast majority of patient data…

Read More